Announced details
Improvement of heavy menstrual bleeding, lower abdominal pain, lower back pain and anemia associated with uterine fibroids. The product is also under development in Japan for endometriosis.
Kissei Pharmaceutical Co., Ltd. discovered and developed the product and is its marketing authorization holder. Overseas, Theramex and シンモサバイオファーマ, among others, are listed as companies to which the technology has been licensed.
Listed drug price: ¥429.10/tablet
No change to the consolidated earnings forecast for the fiscal year ending March 2026.
The company does not address Contract Value.
Nature Reviews Disease Primers (2016, Article number: 16043); Ministry of Economy, Trade and Industry, “Estimation of Economic Losses Due to Women's Health Issues and the Need for Health Management”
| Item | Details |
|---|---|
| Names of Products / Services Covered | Iselty Tablets 100 mg (generic name: linzagolix choline) |
| Relationship with the Company | Kissei Pharmaceutical Co., Ltd. discovered and developed the product and is its marketing authorization holder. Overseas, Theramex and シンモサバイオファーマ, among others, are listed as companies to which the technology has been licensed. |
| Offering price | Listed drug price: ¥429.10/tablet |
| Launch date | 19 March 2026 (already launched) |
| Applicable area | Improvement of heavy menstrual bleeding, lower abdominal pain, lower back pain and anemia associated with uterine fibroids. The product is also under development in Japan for endometriosis. |
| Impact on Business Performance | No change to the consolidated earnings forecast for the fiscal year ending March 2026. |
| Source | Nature Reviews Disease Primers (2016, Article number: 16043); Ministry of Economy, Trade and Industry, “Estimation of Economic Losses Due to Women's Health Issues and the Need for Health Management” |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To provide a new treatment option for uterine fibroids and contribute to creating a society in which women can thrive through disease-awareness activities.